Brentuximab for Newly Diagnosed Hodgkin Disease

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05400122` - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Phase 1
Completed	`NCT01947140` - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies	Phase 1/Phase 2
Recruiting	`NCT05019976` - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma	N/A
Active, not recruiting	`NCT03617666` - Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study	Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Recruiting	`NCT02507479` - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies	Phase 2
Active, not recruiting	`NCT02191930` - Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma	Phase 2
Completed	`NCT01943682` - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma	Phase 1
Completed	`NCT01393106` - Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Terminated	`NCT00992030` - R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma	Phase 3
Terminated	`NCT00722865` - Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma	Phase 2
Unknown status	`NCT00598624` - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)	Phase 2
Completed	`NCT03242902` - To Decrease Fatigue With Light Therapy	Phase 3
Active, not recruiting	`NCT05205512` - Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial	N/A
Recruiting	`NCT03681561` - Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT03250962` - SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Recruiting	`NCT04510610` - Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma	Phase 2/Phase 3
Completed	`NCT06295211` - Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Active, not recruiting	`NCT02256137` - A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
Completed	`NCT02432235` - Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma	Phase 1

NCT number	NCT02398240
Study type	Interventional
Source	New York Medical College
Contact
Status	Completed
Phase	Phase 2
Start date	May 2015
Completion date	December 2022

Brentuximab for Newly Diagnosed Hodgkin Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms